26
Participants
Start Date
September 30, 2009
Primary Completion Date
November 30, 2012
Study Completion Date
October 31, 2013
XL184
XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
temozolomide
TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
temozolomide
TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
Radiation Therapy
Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
temozolomide
TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
Beth Israel Medical Center, New York
University of Virginia Health System/Division of Neuro-Oncology, Charlottesville
Duke University Medical Center; The Preston Robert Tisch Brain Tumor Center, Durham
Henry Ford Health System, Detroit
MD Anderson Cancer Center, Houston
UCLA, Los Angeles
University of Washington, Seattle
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Exelixis
INDUSTRY